HOME >> BIOLOGY >> NEWS
Enzyme once thought harmful to Alzheimers patients now appears key to future treatment

March 12, 2002 -- Bethesda, MD -- The four million Americans who have been diagnosed with Alzheimers disease (AD) experience symptoms which include progressive mental deterioration, confusion, a loss of memory and an inability to calculate the simplest of numbers. This may be due to the fact that people with Alzheimer's have fewer brain cells and less of some important neurotransmitters than people without the disease.

The Importance of Galanin
Previous research has established that a substance called galanin is associated with learning and memory and is involved in brain function, and disorders such as epilepsy. When a nerve is cut or injured, the neuron produces extra galanin, possibly to repair or modulate the damage. The production of galanin may be one way that the body tries to repair nerve damage. Unfortunately, accepted literature states when the onset of AD occurs, galanin hyperinnervation (excessive supply) of nerve cells that employ acetylcholine as their neurotransmitter in the basal forebrain of AD patients occurs and depresses acetylcholine release and its inhibitory actions at other central nervous system sites.

Background
The majority of the scientific community believes this action is detrimental. This is due to a finding that AD wipes out many of the cholinergic neurons of the hippocampus; those that survive in the nucleus show elevated expression of galanin. However, a new study suggests that by virtue of its excitatory actions on cholinergic neurons, galanin may in fact play a compensatory role by enhancing the release of acetylcholine from remaining cholinergic basal forebrain neurons. This action might serve to delay the progression of Alzheimer's disease linked to a reduction in central cholinergic tone. This raises the possibility that induction of galanin by nerve growth factor may have a neuroprotective role.

The Study
To examine this theory, an investigation of the mechanism of action of this
'"/>

Contact: Donna Krupa
djkrupa1@aol.com
703-527-7357
American Physiological Society
14-Mar-2002


Page: 1 2 3

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme mimetic reduces tissue damage in colitis animal study
11. Enzyme studies at Brookhaven Lab may lead to new antiviral agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... , ... April 24, 2019 , ... ... announces today the award of U.S. patent 10,191,929, “Systems and Methods for SNP ... and more efficient to conduct a variety of advanced bioinformatic analyses, including SNP ...
(Date:4/18/2019)... and WALNUT CREEK, Calif. (PRWEB) , ... April ... ... management solution for the healthcare industry, today announced the launch of mSource® AI ... processing to extract deep knowledge of Medpricer customers’ supplier contracts, truly optimizing purchased ...
(Date:4/16/2019)... ... April 16, 2019 , ... HealthLink International, experts ... its new medical device facility on Friday, April 12. Headquartered in the Netherlands, ... new facility includes 108,500 square feet and houses 32 employees enabling HealthLink to ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... , ... April 24, 2019 , ... ... Agents for sales and service organizations, today announced global availability of Inference ... providers and enterprises of all sizes to harness the power of Google’s ...
(Date:4/15/2019)... ... April 15, 2019 , ... ... of a $2 million bench plant expansion to increase production of methylene malonate ... the design and construction of Sirrus’ full-scale production facility, which is scheduled to ...
(Date:4/9/2019)... , ... April 09, 2019 , ... ... focused on increasing the capacity of life sciences organizations to accelerate innovation and ... Assurance platform in the past 12 months. , USDM’s Cloud Assurance ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
Breaking Biology Technology:
Cached News: